Have a personal or library account? Click to login
Programmed Death-Ligand 1, C-reactive Protein, and Neutrophil/Lymphocyte Ratio as Lymphangiogenesis Markers of Metastasis in Penile Cancer – A Systematic Review Cover

Programmed Death-Ligand 1, C-reactive Protein, and Neutrophil/Lymphocyte Ratio as Lymphangiogenesis Markers of Metastasis in Penile Cancer – A Systematic Review

Open Access
|Jan 2024

Abstract

Introduction

The spread of penile cancer cells through lymphatic vessels provides the potential for using compounds involved in lymphangiogenesis, such as programmed death-ligand 1 (PD-L1), C-reactive protein (CRP), neutrophil/lymphocyte ratio (NLR), and Ki-67, in predicting the development of lymphatic metastases in penile cancer.

Methods

The systematic review was conducted based on the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement. A literature search was conducted using the medical literature database PubMed, Scopus, ScienceDirect, EMBASE, and EBSCOHost for studies published until February 7, 2023.

Results

Among 527 studies identified in the literature, 21 studies met the inclusion criteria and became eligible studies. PD-L1, CRP, and NLR are biomarkers which are proven to be significantly associated with an increased risk of high-grade tumor and lymphatic metastasis in penile cancer.

Conclusion

PD-L1, CRP, and NLR are biomarkers that might be used to assess the risk or likelihood of developing lymphatic metastases in penile cancer.

DOI: https://doi.org/10.2478/fco-2023-0010 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Language: English
Page range: 25 - 34
Submitted on: Jun 19, 2023
Accepted on: Nov 6, 2023
Published on: Jan 1, 2024
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2024 I Wayan Yudiana, Stacia Novia Marta, Ronald Sugianto, Anak Agung Wiradewi Lestari, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.